Interim Report

April - June 2026

Saving. Vital. Seconds.

Ortivus' deep domain knowledge and advancements in AI mean that we, with the MobiMed platform, are well positioned to meet the healthcare sector's urgent need for increased efficiency.

April-June 2026

- Net sales decreased by 2% compared to the same period last year and amounted to SEK 19.3 (19.7) million.
- The gross margin decreased to 37 (51)%.
- EBITDA amounted to SEK -2.8 (-4.7) million.
- Net profit after tax amounted to SEK -3.6 (-6.5) million.
- Earnings per share before and after dilution amounted to SEK -0.04 (-0.15).

January-June 2026

- Net sales increased by 8% compared to the same period last year and amounted to SEK 40.8 (37.8) million.
- The gross margin decreased to 42 (46)%.
- EBITDA amounted to SEK -2.9 (-6.1) million.
- Net profit after tax amounted to SEK -4.9 (-8.9) million.
- Earnings per share before and after dilution amounted to SEK -0.06 (-0.20).

Significant events during and after the end of the period

- In April, Ortivus announced the appointment of Matti Zemack as the company's new Chief Product Officer. Zemack will be responsible for the company's product vision and product development, and will lead the next generation of Ortivus' innovative medical technology solutions within e-health.
- In April, Ortivus held its annual User Forum in Southampton, UK. With strong participation from our UK customers, new solutions within the MobiMed platform were presented and discussed.
- In May, Ortivus announced that the company had divested all its shares in the technology company H&E Solutions AB for a purchase price of SEK 5.2 million. The sale generated an accounting profit of SEK 2.9 million and strengthened Ortivus' liquidity, while the successful collaboration on MobiMed enRoute continued unchanged.
- Ortivus held its Annual General Meeting on 27 May 2026.
- In July, Ortivus strengthened the MobiMed platform with AI-based clinical documentation through a new partnership with Tortus AI.
- Ortivus intends to transition to semi-annual financial reporting, meaning that the interim report for the third quarter, previously scheduled for 13 November 2026, will not be published. The company's next financial report will therefore be the Year-End Report for 2026.

The Group's key figures

Amount in KSEK	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Net sales	19,313	19,659	40,802	37,802	73,401
Gross margin (%)	37%	51%	42%	46%	40%
Adjusted gross margin	37%	51%	42%	46%	43%
EBITDA	-2,783	-4,678	-2,855	-6,086	-15,943
Operating profit	-6,136	-5,276	-7,219	-7,736	-19,805
Net profit after tax	-3,572	-6,462	-4,921	-8,911	-21,876
Equity ratio (%)	24%	-26%	24%	-26%	32%
Earnings per share, before and after dilution, SEK	-0.04	-0.15	-0.06	-0.20	-0.43
Equity per share, before and after dilution, SEK	0.20	-0.37	0.20	-0.37	0.25

CEO's Statement

MobiMed - the digital platform for a changing healthcare landscape

The UK Government's policy report Fit for the future: 10 Year Health Plan for England identifies three critical shifts for the NHS: from hospital to community care, from analogue to digital ways of working, and from treating illness to preventing it. For ambulance services, this transformation means a shift from transport to treatment. It is no longer solely about transporting patients quickly to the emergency department, but on being able to assess their care needs at the pre-hospital stage, make well-informed decisions and, where appropriate, provide the required care at the scene. This shift is already under way in both the UK and Singapore, delivering very significant savings for these healthcare systems each year.

For this transformation to succeed fully, more than individual digital tools are required. It depends on ambulance services, community care, social care and virtual wards being able to work more closely together and in real time. When the right information is available to the right healthcare professional, there is greater scope to identify deterioration at an early stage, provide appropriate care in the patient's home and avoid unnecessary hospital admissions.

It is in this context that MobiMed is already creating value for our customers in the UK, Sweden and Singapore.

The MobiMed platform is designed around the workflows of mobile healthcare, connecting information, people and processes throughout the entire care pathway. By making relevant patient information and clinical decision support available even in environments with limited connectivity, MobiMed can reduce administrative burden, strengthen patient safety and facilitate handovers between healthcare professionals and organisations. It also enables ambulance personnel to return to operational readiness and take their next call more quickly, supporting both patient safety and productivity while contributing to more efficient use of public funds.

The platform addresses healthcare needs through a range of practical applications. With **MobiMed Pocket**, for example, community healthcare professionals, as well as doctors, can access essential information directly on their mobile phones. Through **MobiMed Video Decision Support**, enabled by our integration with Pexip, healthcare professionals can communicate and collaborate remotely when the situation requires it. In the UK, we are also partnering with Tortus AI, with **MobiMed AVT** (Ambient Voice Technology) automatically transcribing and summarising conversations with patients directly into the electronic patient care record. This saves time while helping ensure that essential information is documented and that nothing important is lost during handover.

This autumn, we are also launching **MobiMed Insight**, a module within the MobiMed platform for data-driven operational management and performance monitoring. By leveraging operational data, MobiMed Insight highlights further opportunities to save time and costs, as well as opportunities for clinical improvement.

Ortivus continues to invest in the MobiMed platform and can now offer customers faster and simpler implementation through a SaaS application for both Windows and iOS. This enables us to roll out MobiMed more rapidly across new geographical markets. Australia is one example, where we now have established a presence, and we are also evaluating opportunities in other English-speaking markets.

In Sweden, the rollout of the latest generation of MobiMed continues according to plan and will continue into 2027.

At the same time as we continue to invest in our development organisation, we are seeing how rapid advances in AI are continually creating new opportunities for Ortivus. AI allows us to work faster and more efficiently, while improving quality and accelerating the development and testing of new functionality. For an organisation with deep domain expertise and a strong understanding of its customers, AI is a particularly powerful tool. We are already seeing a significant increase in productivity and how the technology can help us translate our expertise into tangible customer value more quickly.

Ortivus' deep domain knowledge and advancements in AI mean that we, with the MobiMed platform, are well positioned to meet the healthcare sector's urgent need for increased efficiency.

GUSTAF NORDENHÖK
Chief Executive Officer

Group development April – June 2026

Financial performance for the quarter

Net sales for the quarter decreased by 2% and amounted to SEK 19.3 (19.7) million. Of the quarter's net sale, SEK 9.1 million relate to recurring contracts. The gross margin for the quarter was 37 (51)%. The lower gross margin is explained by the increase in hardware sales, primarily driven by hardware replacements at our customers. Operating expenses for the quarter amounted to SEK 13.3 (15.2) million. The change by cost category between the years is mainly due to an adjustment of the reporting structure reflecting increase license and service sales and reduced hardware sales. Selling expenses decreased to SEK -4.1 (-5.1) million as an effect of changed reporting of work connected to the service contracts accounted for in the gross margin. Administrative expenses increased to SEK -4.9 (-3.7) million as an effect of changed reporting structure. Research and development expenses increased to SEK -3.7 (-1.3) million, mainly due to lower level of capitalisation of expenses compared to last year. Other operating income increased to SEK 0.2 (0.1) million by unrealised exchange profit. Other operating costs decrease to SEK -0.7 (-5.2) million, due to 2025 debited by one-time costs of SEK -5.1 million for closing the business in Estonia. Included in costs 2026 is SEK 0.7 million of unrealised exchange losses. Operating profit for the quarter amounted to SEK -6.1 (-5.3) million. Profit from financial assets is due to the sales of shares in the technical company H&E Solutions AB, with a profit of SEK 2.9 million, and costs for the liquidation of the fully owned Danish subsidiary Ortivus MobiMed ApS of SEK -0.2 million. Financial net, primarily consisting of interest on borrowings, amounted to SEK -0.2 (-1.2) million for the quarter. Profit after tax for the quarter amounted to SEK -3.6 (-6.5) million, corresponding to earnings per share before and after dilution of SEK -0.04 (-0.15).

Financial development during the semi-annual

Net sales for the semi-annual increased by 8% and amounted to SEK 40.8 (37.8) million. Of the semi-annual's net sale, SEK 17.9 million relate to recurring contracts. The increase in revenue was primarily driven by hardware replacements at our customers, as well as the rollout of MobiMed 5 with additional services. The gross margin for the semi-annual amounted to 42 (46)%. The lower gross margin is explained by increased hardware sales in the second quarter primarily driven by hardware replacements at our customers. Operating expenses for the quarter amounted to SEK 24.4 (25.3) million. The change by cost category between the years is mainly due to an adjustment of the reporting structure reflecting increase license and service sales and reduced hardware sales. Selling expenses decreased to SEK -7.7 (-10.6) million as an effect of changed reporting of work connected to the service contracts accounted for in the gross margin. Administrative expenses increased to SEK -9.7 (-6.2) million as an effect of changed reporting structure. Research and development expenses increased to SEK -6.3 (-3.3) million, mainly due to lower level of capitalisation of expenses compared to last year. Other operating income increased to SEK 0.7 (0.1) million by unrealised exchange profit. Other operating costs decrease to SEK -1.5 (-5.3) million, due to 2025 debited by one-time costs of SEK -5.1 million for closing the business in Estonia. Included in costs 2026 is SEK 1.4 million of unrealised exchange losses. Operating profit for the quarter amounted to SEK -7.2 (-7.7) million. Profit from financial assets is due to the sales of shares in the technical company H&E Solutions AB, with a profit of SEK 2.9 million, and costs for the liquidation of the fully owned Danish subsidiary Ortivus MobiMed ApS of SEK -0.2 million. Financial net, primarily consisting of interest on borrowings, amounted to SEK -0.5 (-1.2) million for the semi-annual. Profit after tax for the quarter amounted to SEK -4.9 (-8.9) million, corresponding to earnings per share before and after dilution of SEK -0.06 (-0.20).

Cash flow and liquidity during the quarter

Cash flow from operating activities was positive SEK 1.3 (-4.8) million for the quarter. Cash flow from investing activities amounted SEK -1.8 (-3.4) million for the quarter. Cash flow from financing activities generated SEK 0 (7.6) million for the quarter. The Group's total cash flow amounted SEK -0.5 (-0.5) million for the quarter.

Cash flow and liquidity during the semi-annual

Cash flow from operating activities was negative SEK -6.0 (-9.6) million for the semi-annual. Cash flow from investing activities amounted SEK -3.2 (-6.6) million for the semi-annual. Cash flow from financing activities generated SEK 7.0 (10.5) million related to increased borrowings for the semi-annual. The Group's total cash flow amounted SEK -2.2 (-5.7) million for the semi-annual. Cash and cash equivalents at the end of the period totalled SEK 6.7 (1.6) million.

Financial position

Fixed assets: Intangible and tangible fixed assets amounted to SEK 38.3 (34.3) million. During the quarter investments in intangible fixed assets amounted SEK 1.2 (3.9) million and for the semi-annual SEK 2.6 (6.6) million, with depreciations for the quarter of SEK 0.4 (0.8) million and for the semi-annual of SEK 2.6 (6.6) million. The investments comprised the capitalisation of development expenses for iOS and MobiMed. Right-of-use assets amounted to SEK 6.1 (2.9) million at the end of the period and are entirely attributable to lease expenses for premises. Financial assets amounted to SEK 0.0 (2.3) million. The decrease comprises the sale of shares in the technical company H&E Solutions AB.

Current assets: Inventory at the end of the period amounted to SEK 5.3 (6.0) million. Accounts receivable amounted to SEK 11.7 (8.8) million and increased with larger deliveries of hardware and invoicing at the end of the semi-annual. Other receivables increased to SEK 1.5 (0.8) million. Prepaid expenses and accrued income decreased to SEK 4.1 (5.0) million.

Liabilities and Equity: Group Equity at the end of the period amounted to SEK 17.8 (-16.2) million with an equity ratio of 24 (-26)%. The improvement in 2026 comprises of the directed rights issue at the end of 2025. Long-term liabilities amounted to SEK 28.8 (45.4) million consists of loans to Ponderus Invest AB of SEK 25 million and lease liabilities of SEK 3.8 million. Short term liabilities amounted to SEK 27.2 (32.5) million. Advanced payments from customers have decreased to SEK 3.3 (5.3) million. Account payables decreased to SEK 6.4 (7.9) million. Other liabilities decreased to SEK 3.5 (5.2) million. Short term lease liabilities of SEK 1.8 (2.0) million and Accrued expenses and prepaid income of SEK 12.2 (12.2) million are in line with previous year.

The Group
The Group comprises the Parent Company Ortivus AB (publ), corporate ID 556259–1205, as well as the subsidiaries Ortivus UK Ltd, corporate ID 03558696, Ortivus MobiMed AB, corporate ID 556593–0707 as well as Ortivus APAC PTY Ltd. The wholly owned subsidiary Ortivus MobiMed ApS, CVR No. 43419110 has underdone a voluntary liquidation, which was completed in June 2026. The subsidiary Ortivus APAC PTY Ltd is currently being established in Australia.

Personnel
At the end of the semi-annual the Group employed 32 (31) people, with 2 (2) in the Parent Company. Employees in Sweden numbered 26 (23). The proportion of women was 29 (30)%. Seven consultants work in the company in varying levels of engagement.

Related party transactions
The existing credit facility from Ponderus Invest AB remains in place until the 30th November 2027. Ponderus Invest AB holds 80.3% of the shares and are represented on the Board of Directors.

Shares, share capital and shareholders
Ortivus A- and B-shares are listed on Nasdaq First North Growth Market. As of 30 June, the number of shares amounted to 88.6 million, comprising 1.6 million A-shares and 87 million B-shares. The number of shareholders amounted to 2,874. The company's market capitalisation at the end of the period amounted to SEK 158.0 (62.5) million.

Forward-looking statements
All forward-looking statements in this report are based on the company's best assessment at the time of the report. Such statements involve risks and uncertainties, which may result in actual outcomes differing. Except as required by applicable law, forward-looking statements are valid only as of the date they are made, and Ortivus undertakes no obligation to update any of them in light of new information or future events. Ortivus does not provide forecasts.

Other
The Parent Company, Ortivus AB (publ) conducts group-wide operations. The Parent Company's net sales during the quarter amounted to SEK 3.7 (5.3) million and for the semi-annual SEK 7.6 (9.6) million. Operating profit for the quarter amounted to SEK -0.6 (-0.0) million and for the semi-annual to SEK -0.2 (1.7) million. The Parent Company have strengthened the share capital of Ortivus MobiMed AB with unconditional shareholders contribution. The shares in the subsidiary are written down with the same amount in parallel, accounted for as loss from shares in Group companies amounting SEK -10.8 (0) million. Cash and cash equivalents in the Parent Company at the end of the semi-annual totalled SEK 1.6 (0.0) million.

Certified Adviser
Certified Adviser on NASDAQ First North Growth Market is FNCA Sweden AB
Box 5807
Nybrogatan 34
102 48 Stockholm
Phone: +46 8 528 00 399

Financial calender
Year-end Report for 2026: 19 February 2027
Annual Report for 2026: 7 April 2027
Annual General Meeting: 12 May 2027
Interim Report for 2027: 25 August 2027
Year-end Report for 2027: 18 February 2028

Financial information
Ortivus AB (publ) is listed on Nasdaq First North Growth Market. The information in this report is disclosed in accordance with the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication through the agency of the contact persons below on 25 August 2026, at 08:30 CET. Financial reports and press releases are published in Swedish and English and are available at www.ortivus.com.

This report has not been reviewed by the company's auditor.

For further information:

Gustaf Nordenhök, CEO
Phone: +46 (0) 73-2624357
Email: gustaf.nordenhok@ortivus.com

Assurance
The Board of Directors and the CEO certify that this report provides a fair overview of the Parent Company's and the Group's operations, financial position, and results, and describes the significant risks and uncertainties facing the Parent Company and the companies in the Group.

Danderyd 08-25-2026

Anna-Carin Strandberg
Chairman of the Board

Peter Edwall
Board member

Anna Klevby Dalgaard
Board member

Gustaf Nordenhök
Chief Executive Officer

Financial reports
The Group

The Group's report on results in summary

Amount in KSEK	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Net sales	19,313	19,659	40,802	37,802	73,401
Cost of sales	-12,169	-9,703	-23,621	-20,260	-43,801
Gross profit	**7,144**	**9,956**	**17,181**	**17,542**	**29,600**
Gross margin	**37%**	**51%**	**42%**	**46%**	**40%**
Selling expenses	-4,106	-5,055	-7,708	-10,554	-20,875
Administrative expenses	-4,946	-3,690	-9,658	-6,214	-15,466
Research and development expenses	-3,733	-1,347	-6,262	-3,288	-7,707
Other operating income	240	64	726	95	1,563
Other operating expenses	-735	-5,204	-1,498	-5,317	-6,920
Operating profit	**-6,136**	**-5,276**	**-7,219**	**-7,736**	**-19,805**
Operating margin	**-32%**	**-27%**	**-18%**	**-20%**	**-27%**
Result from other financial non-current	2,793	-	2,793	-	-
Financial net	-229	-1,186	-495	-1,175	-1,858
Profit before tax	**-3,572**	**-6,462**	**-4,921**	**-8,911**	**-21,663**
Tax	-	-	-	-	-213
Profit for the period	**-3,572**	**-6,462**	**-4,921**	**-8,911**	**-21,876**
Items that may be subsequently reclassified to profit or loss					
Gains/losses arising on translation of the statements of foreign operations	176	-140	348	-140	-683
Comprehensive income for the period	**-3,396**	**-6,602**	**-4,573**	**-9,051**	**-22,559**
Profit for the period attributable to Owners of the Parent Company	-3,572	-6,462	-4,921	-8,911	-21,876
Comprehensive income for the period attributable to Owners of the Parent Company	-3,396	-6,602	-4,573	-9,051	-22,559

The Group's statement of financial position in summary

Amount in KSEK	30/Jun 2026	30/Jun 2025	31/Dec 2025
Fixed assets			
Intangible assets	37,878	33,457	36,297
Tangible assets	462	857	562
Right-of-use assets	6,137	2,865	1,951
Financial assets	37	2,348	2,347
Total fixed assets	**44,514**	**39,527**	**41,157**
Current assets			
Inventory	5,274	6,007	4,663
Accounts receivable	11,705	8,799	9,965
Other receivable	1,524	761	906
Prepaid expenses and accrued income	4,189	5,047	5,350
Cash	6,696	1,599	8,888
Total current assets	**29,388**	**22,213**	**29,772**
TOTAL ASSETS	**73,902**	**61,740**	**70,929**
SHAREHOLDER'S EQUITY	**17,841**	**-16,216**	**22,414**
PROVISIONS	**-**	**83**	**87**
Long term liabilities			
Long-term interest-bearing liabilities	-	1,197	-
Loan	25,000	44,169	18,000
Lease liabilities	3,835	-	-
Total long term liabilities	**28,835**	**45,366**	**18,000**
Short term liabilities			
Advance payments from customers	3,296	5,296	4,459
Accounts payable	6,404	7,913	8,165
Other liabilities	3,530	5,169	4,256
Lease liabilities	1,792	1,957	1,527
Accrued expenses and prepaid income	12,204	12,172	12,021
Total short term liabilities	**27,226**	**32,507**	**30,428**
TOTAL LIABILITIES AND EQUITY	**73,902**	**61,740**	**70,929**

The Group's statement of changes in equity

Amount in KSEK	30/Jun 2026	30/Jun 2025	31/Dec 2025
Opening balance	22,414	-7,165	-7,165
Profit for the period	-4,921	-8,911	-21,876
Rights issue	-	-	52,139
Currency adjustment	348	-140	-683
Closing balance	17,841	-16,216	22,414

The Group's statement of cash flow in summary

Amount in KSEK	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Profit before tax	-3,572	-6,461	-4,921	-8,911	-21,663
Adjustments for non-cash items	827	1,660	1,572	2,329	-1,890
Cash flow from operating activities before changes in working capital	**-2,745**	**-4,801**	**-3,349**	**-6,582**	**-23,553**
Cash flow from changes in working capital	4,067	47	-2,638	-2,984	-1,684
Cash flow from operating activities	**1,322**	**-4,754**	**-5,987**	**-9,566**	**-25,237**
Cash flow from investing activities	-1,773	-3,353	-3,205	-6,612	-9,630
Cash flow from financing activities	-	7,571	7,000	10,496	36,475
Cash flow for the period	**-451**	**-536**	**-2,192**	**-5,682**	**1,608**
Cash at the beginning of the period	7,147	2,135	8,888	7,281	7,281
Cash at the end of the period	**6,696**	**1,599**	**6,696**	**1,599**	**8,888**

Financial reports

The Parent Company

The Parent Company's income statement in summary

Amount in KSEK	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Net sales	3,688	5,273	7,635	9,566	20,977
Cost of sales	-	-2,982	-	-2,982	-
Gross profit	**3,688**	**2,291**	**7,635**	**6,584**	**20,977**
Gross margin	**100%**	**43%**	**100%**	**69%**	**100%**
Administrative expenses	-4,279	-2,288	-7,870	-4,741	-17,635
Research and development expenses	-	-123	-	-123	-
Other operating income	-	-8	-	-	-
Other operating expenses	-	125	-	-	-
Operating profit	**-591**	**-3**	**-235**	**1,720**	**3,342**
Operating margin	**-16%**	**0%**	**-3%**	**18%**	**16%**
Result from investments in group companies	-10,846	-	-10,846	-	-
Financial net*	-380	-805	-659	-1,510	-2,876
Profit before tax	**-11,817**	**-808**	**-11,740**	**210**	**466**
Tax	-	-	-	-	-
Profit for the period	**-11,817**	**-808**	**-11,740**	**210**	**466**

*) Interest expenses for Q1 have been reclassified from operating expenses and are included in the accumulated net financial result.

The Parent Company's statement of financial position in summary

Amount in KSEK	30/Jun 2026	30/Jun 2025	31/Dec 2025
Fixed assets			
Intangible assets	1,075	1,107	1,229
Participation in group companies	60,009	60,009	60,009
Total fixed assets	**61,084**	**61,116**	**61,238**
Current assets			
Accounts receivables	-	119	-
Receivables from group companies	38,759	20,685	44,162
Tax receivables	241	278	160
Other receivables	-	-	666
Prepaid expenses and accrued income	452	605	814
Cash	1,623	3	1,831
Total current assets	**41,075**	**21,690**	**47,633**
TOTAL ASSETS	**102,159**	**82,806**	**108,871**
SHAREHOLDER'S EQUITY	**72,720**	**32,064**	**84,459**
Long term liabilities			
Long-term loans	25,000	43,664	18,000
Total long term liabilities	**25,000**	**43,664**	**18,000**
Short term liabilities			
Advance payments from customers	1,091	1,049	350
Accounts payable	910	1,472	3,946
Liabilities to group companies	-	753	-
Other liabilities	606	74	219
Accrued expenses and prepaid income	1,832	3,730	1,897
Total short term liabilities	**4,439**	**7,078**	**6,412**
TOTAL LIABILITIES AND EQUITY	**102,159**	**82,806**	**108,871**

Note 1 General information
Ortivus AB (publ), corporate identity number 556259-1205, is a Swedish public limited company with its registered office in Danderyd. The head office is located at Svärdvägen 19, SE-182 33 Danderyd, Sweden. The Group provides digital medical technology and eHealth solutions, specifically developed for out-of-hospital care. Unless otherwise stated, all amounts are reported in thousands of SEK (KSEK). Figures in parentheses refer to the comparative period. This interim report was approved for publication by the Board of Directors on 25th August 2026.

Note 2 Accounting principles
This report for the Group has been prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. The report for the Parent Company has been prepared in accordance with the Swedish Annual Accounts Act. The same accounting and valuation principles have been applied for the Group and the Parent Company as in the most recently published annual report. Significant estimates and judgements are described in Note 29 of the 2025 Annual Report.

Note 3 Significant risks and uncertainties
Due to the nature of its operations, Ortivus is exposed to various types of risks. The Board's work on risk management is outlined in Note 26 of the 2025 Annual Report.

Note 4 Revenue distribution
The Group has only one operating segment, which is fully reflected in the Group's financial reports. Revenue is distributed geographically as shown in the table below.

	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Nordics	12,274	6,187	21,901	16,000	31,787
Rest of Europe	6,676	13,003	18,188	20,958	40,071
Rest of the World	363	469	713	844	1,543
Total	**19,313**	**19,659**	**40,802**	**37,802**	**73,401**

Note 5 Significant exchange rates

30 June 2026	EUR	GBP	SGD	USD
Closing rate	11.09	12.87	7.52	9.74
Average rate Q2	10.88	12.57	7.31	9.36
Average rate H1	10.79	12.44	7.24	9.25

30 June 2025	EUR	GBP	SGD	USD
Closing rate	11.15	13.03	7.46	9.51
Average rate Q2	10.95	12.90	7.43	9.67
Average rate H1	11.10	13.18	7.68	10.19

Note 6 Alternative performance measures
Ortivus applies the European Securities and Markets Authority's (ESMA) guidelines for so-called Alternative Performance Measures (APMs). The company's management considers these alternative performance measures to be relevant for users of the financial report as a complement to the metrics that reflect the company's operational development. These financial measures are not always comparable with those used by other companies, as not all companies calculate such measures in the same way. Therefore, these financial measures should not be regarded as substitutes for measures defined in accordance with IFRS.

Definitions of key performance indicators
The Group

Gross margin - Gross profit as a percentage of net sales. The company believes that key figures provide a deeper understanding of the company's profitability.

Amount in KSEK	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Gross profit/	7,144	9,956	17,181	17,542	29,600
Net sales	19,313	19,659	40,802	37,802	73,401
Gross margin	**37%**	**51%**	**42%**	**46%**	**40%**

Adjusted gross margin - Adjusted gross margin for non-recurring items. Significant events and transactions that are relevant when comparing results between periods are highlighted. Non-recurring items comprise restructuring costs, consultancy fees, costs related to staff reductions, contract losses, impairments, significant customer losses, as well as legal disputes and insurance claims. Non-recurring items are excluded to facilitate comparison of results across periods.

Amount in KSEK	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Gross profit	7,144	9,956	17,181	17,542	29,600
Non-recurring items	-	-	-	-	2,240
Adjusted gross profit/	7,144	9,956	17,181	17,542	31,840
Net sales (adjusted)	19,313	19,659	40,802	37,802	73,401
Adjusted gross margin	**37%**	**51%**	**42%**	**46%**	**43%**

Operating margin - Operating margin as a percentage of net sales. The Company believes that key figures provide a deeper understanding of the company's profitability.

Amount in KSEK	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Operating results/	-6,136	-5,276	-7,219	-7,736	-19,805
Net sales	19,313	19,659	40,802	37,802	73,401
Operating margin	**-32%**	**-27%**	**-18%**	**-20%**	**-27%**

EBITDA - Operating profit before net interest, tax, depreciation of tangible and intangible fixed assets. The company believes that the key figure provides a deeper understanding of the company's profitability.

Amount in KSEK	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Profit before tax	-3,572	-6,462	-4,921	-8,911	-21,663
Financial net	229	1,186	495	1,175	1,858
Depreciation	560	597	1,572	1,650	3,862
EBITDA	**-2,783**	**-4,678**	**-2,855**	**-6,086**	**-15,943**

Adjusted EBITDA - Adjusted EBITDA for non-recurring items. Significant events and transactions that are relevant when comparing results between periods are highlighted. Non-recurring items comprise restructuring costs, such as consultancy fees, staff reductions, contract losses, and impairments. Non-recurring items are excluded to facilitate comparability of results across periods.

Amount in KSEK	Apr-Jun 2026	Apr-jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
EBITDA	-2,783	-4,678	-2,855	-6,086	-15,943
Non-recurring items	-	5,078	-	5,078	7,361
Adjusted EBITDA	**-2,783**	**400**	**-2,855**	**-1,008**	**-8,582**

Equity ratio - Equity as a percentage of total assets. Equity ratio shows what proportion of the balance sheet total is made up of equity and has been included so that investors can form a picture of the company's capital structure.

Amount in KSEK	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Equity at the end of the period/	17,841	-16,216	17,841	-16,216	22,414
The balance sheet	73,902	61,740	73,902	61,740	70,929
Equity ratio	**24%**	**-26%**	**24%**	**-26%**	**32%**

Earnings per share - Profit after tax divided by the average number of shares for the period.

Amount in KSEK	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Profit after tax	-3,572	-6,462	-4,921	-8,911	-21,876
Average number of shares for the period	88,615	44,307	88,615	44,307	51,469
Earnings per share	**-0.04**	**-0.15**	**-0.06**	**-0.20**	**-0.43**

Equity per share - Equity at the end of the period divided by the number of shares at the end of the period. The company considers this key figure to provide a deeper understanding of the company's profitability.

Amount in KSEK	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Equity at the end of the period/	17,841	-16,216	17,841	-16,216	22,414
Number of shares at the end of the period	88,615	44,307	88,615	44,307	88,615
Equity per share	**0.20**	**-0.37**	**0.20**	**-0.37**	**0.25**



Ortivus

To ensure a smooth and efficient healthcare pathway

Our vision
Helping healthcare organisations provide the best possible care to their patients.

Our mission
To create and implement innovative software solutions that facilitate diagnosis in healthcare delivery, ultimately improving the health and well-being of people worldwide.

Our business idea
Ortivus primarily works within ambulance services and pre-hospital care. We specialise in electronic patient care records (ePCR) and complementary digital solutions.

Ortivus platform

MobiMed

MobiMed ePR
MobiMed ePR gathers all essential patient information in an intuitive interface, making it easier to make informed decisions in real time and ensuring high-quality care documentation.

MobiMed Monitor
MobiMed Monitor enables real-time monitoring of vital signs directly in the ambulance, providing a stronger basis for decision-making during emergency interventions.

MobiMed FleetCtrl
MobiMed FleetCtrl offers automated checks, status monitoring, and seamless communication between vehicles and personnel, reducing operational disruptions and improving availability.

MobiMed enRoute
MobiMed enRoute combines advanced navigation with case management, facilitating planning, communication, and follow-up during every mission.

MobiMed Life
MobiMed Life is a portable, standalone defibrillator solution that provides immediate access to life-saving treatment and complements the ambulance's existing equipment.

Ortivus AB

Address
Box 713
Svärdvägen 19
182 33 Danderyd
Sweden

Email
info@ortivus.com

www.ortivus.com

Phone
+46 (0) 8 446 45 00

Saving. Vital. Seconds.